公开(公告)号：US20190060398A1

公开(公告)日：2019-02-28

申请号：US15918044

申请日：2018-03-12

Applicant: Biogen MA Inc.

Inventor： Sha Mi ,  R. Blake Pepinsky ,  John McCoy

IPC: A61K38/17 ,  C07K16/18 ,  A61K39/395 ,  C07K14/47 ,  C07K14/705 ,  A61K31/70 ,  C12N5/079 ,  A61K38/00 ,  A61K48/00

Abstract: The invention provides methods of treating diseases, disorders or injuries involving demyelination and dysmyelination, including multiple sclerosis, by the administration of a LINGO-4 antagonist.

公开(公告)号：US20160213745A1

公开(公告)日：2016-07-28

申请号：US14978289

申请日：2015-12-22

Applicant: Biogen MA Inc.

Inventor： Sha Mi ,  R. Blake Pepinsky ,  John McCoy

IPC: A61K38/17 ,  C07K16/18 ,  C07K14/47 ,  A61K39/395

CPC classification number: A61K38/1709 ,  A61K31/70 ,  A61K38/00 ,  A61K39/3955 ,  A61K48/00 ,  C07K14/47 ,  C07K14/70503 ,  C07K16/18 ,  C07K2317/76 ,  C07K2319/30 ,  C12N5/0622 ,  C12N2501/998 ,  C12N2502/08 ,  Y02A50/406

Abstract: The invention provides methods of treating diseases, disorders or injuries involving demyelination and dysmyelination, including multiple sclerosis, by the administration of a LINGO-4 antagonist.

Abstract translation: 本发明提供了通过施用LINGO-4拮抗剂治疗涉及脱髓鞘和脱髓鞘疾病（包括多发性硬化）的疾病，病症或损伤的方法。

公开(公告)号：US20160002329A1

公开(公告)日：2016-01-07

申请号：US14734144

申请日：2015-06-09

Applicant: Biogen MA Inc.

Inventor： Sha Mi ,  R. Blake Pepinsky ,  John McCoy

IPC: C07K16/28 ,  C07K16/40

CPC classification number: C07K16/28 ,  A01K67/0275 ,  A01K67/0276 ,  A01K2217/075 ,  A01K2227/105 ,  A01K2267/0393 ,  A61K2039/505 ,  C07K14/4702 ,  C07K16/18 ,  C07K16/2863 ,  C07K16/32 ,  C07K16/40 ,  C07K2317/74 ,  C07K2317/75 ,  C07K2317/76 ,  C07K2317/92 ,  C07K2319/30 ,  C12N15/8509

Abstract: The invention provides methods of treating diseases, disorders or injuries involving demyelination and dysmyelination, including multiple sclerosis, by the administration of an Sp35 antagonist. Additional methods include methods for inhibiting the binding of the Sp35 polypeptide with the ErbB2 polypeptide and a method for increasing ErbB2 phosphorylation by contacting oligodendrocytes with an effective amount of a composition comprising an Sp35 antagonist of the invention. Further embodiments of the invention include methods of inhibiting the binding of the Sp35 polypeptide with the ErbB2, increasing ErbB2 phosphorylation and promoting oligodendrocyte differentiation comprising contacting oligodendrocyte or oligodendrocyte progenitor cells with an ErbB2 binding agent.

Abstract translation: 本发明提供了通过施用Sp35拮抗剂治疗涉及脱髓鞘和髓鞘脱离（包括多发性硬化）的疾病，病症或损伤的方法。 另外的方法包括用于抑制Sp35多肽与ErbB2多肽的结合的方法以及通过使少突胶质细胞与有效量的包含本发明的Sp35拮抗剂的组合物接触来增加ErbB2磷酸化的方法。 本发明的其它实施方案包括抑制Sp35多肽与ErbB2结合的方法，增加E​​rbB2磷酸化和促进少突胶质细胞分化，包括使少突胶质细胞或少突胶质细胞祖细胞与ErbB2结合剂接触。

公开(公告)号：US20200297800A1

公开(公告)日：2020-09-24

申请号：US16782908

申请日：2020-02-05

Applicant: Biogen MA Inc.

Inventor： Sha Mi ,  R. Blake Pepinsky ,  John McCoy

IPC: A61K38/17 ,  A61K31/70 ,  C07K14/705 ,  C12N5/079 ,  A61K39/395 ,  C07K14/47 ,  C07K16/18

Abstract: The invention provides methods of treating diseases, disorders or injuries involving demyelination and dysmyelination, including multiple sclerosis, by the administration of a LINGO-4 antagonist.